27 June 2024

By Cheow Ming Liang / <u>cheowml@kenanga.com.my</u>



Source: TradingView

About the Stock:			ł			Key Support & Resistance Levels	
Name	:	TMC LIFE SCIENCES Bhd	52 Week High/Low	:	RM0.81/RM0.58	Last Price Resistance	:RM0.675 :RM0.735 (R1) RM0.755 (R2)
Bursa Code CAT Code	:	TMCLIFE 0101	3-m Avg. Daily Vol. Free Float (%)	:	951,698 17	Take Profit Stop Loss	: RM0.733 (RT) RM0.733 (R2) : RM0.740 : RM0.620
Market Cap	:	RM1.176b	Beta vs. KLCI	:	0.7	•	

TMCLIFE BERHAD (Technical Buy)

- TMC Life Sciences BHD (TMCLIFE) made a notable breakout yesterday, closing firmly above its critical 5-day and 13-day Simple Moving Average (SMA) levels with a significant 5.5% gain, reaching RM0.675. The appearance of a hammer candlestick confirms a bullish reversal, with the 5-day SMA beginning to trend upwards, indicating a potential upward movement.
- The trading volume has also surged alongside the price, suggesting that bullish momentum is building. On the technical front, both the daily Stochastic Oscillator and the Tom Demark Pressure Ratio (TDRP) are rebounding from oversold conditions, further supporting the likelihood of a trend reversal. The weekly chart also reflects a similar pattern, pointing to a possible bullish shift ahead.
- Looking forward, a continued upward movement and a break above the immediate resistance at RM0.685 (aligned with the 200-day SMA) would solidify the bullish trend, potentially propelling the stock to close the previous gap at RM0.735. However, if the stock falls below the RM0.65 support level, it could signal a continuation of the downtrend towards the next major support at RM0.63.
- For a strategic entry, consider buying around RM0.66 (near the 13-day SMA). A take-profit target at RM0.74 offers an attractive upside potential of about 12.1%. To manage risk, a stop-loss at RM0.62 is recommended, limiting the potential downside to around 6%. This approach provides a favourable risk-to-reward ratio, making it an appealing trade setup for investors.

This document has been prepared for general circulation based on information obtained from sources believed to be reliable but we do not make any representations as to its accuracy or completeness. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may read this document. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees. Kenanga Investment Bank Berhad accepts no liability whatsoever for any direct or consequential loss arising from any use of this document or any solicitations of an offer to buy or sell any securities. Kenanga Investment Bank Berhad and its associates, their directors, and/or employees may have positions in, and may effect transactions in securities mentioned herein from time to time in the open market or otherwise, and may receive brokerage fees or act as principal or agent in dealings with respect to these companies. Kenanga Investment Bank Berhad being a full-service investment bank offers investment banking products and services and acts as issuer and liquidity provider with respect to a security that may also fall under its research coverage.

Published by:

KENANGA INVESTMENT BANK BERHAD (15678-H)

Level 17, Kenanga Tower, 237, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia Telephone: (603) 2172 0880 Website: www.kenanga.com.my E-mail: research@kenanga.com.my

kenanga 🔪